#USA #New York #Levi & Korsinsky #securities lawsuit #Baxter International

Urgent Notice for Baxter International, Inc. Investors

Introduction
Investors who hold shares in Baxter International, Inc. are strongly encouraged to reach out to Levi & Korsinsky, LLP before the deadline of December 15, 2025. The firm is currently handling a class action lawsuit concerning significant allegations of securities fraud that may have affected numerous stakeholders. This article aims to shed light on the lawsuit, its background, and the options available for investors affected by these developments.

Background of the Lawsuit
Levi & Korsinsky, LLP has officially notified shareholders of Baxter International regarding the ongoing class action lawsuit that targets the company’s alleged misconduct. The class action seeks restitution for losses incurred by investors within a specific timeframe, from February 23, 2022, to October 29, 2025. Potential plaintiffs are encouraged to understand their rights and the options available to them under this legal framework.

The allegations center on motions suggesting the company may have misrepresented critical information about the safety and efficacy of its recently launched Novum LVP product. It is claimed that this product suffered from serious systemic defects leading to malfunction, which posed severe risks to patient safety.

Details of Allegations
The complaint against Baxter asserts that the company:
1. Concealed Product Defects: Baxter's new product, the Novum LVP, allegedly had systemic defects resulting in severe malfunctions. These failures included underinfusion and overinfusion scenarios, which potentially jeopardized patient lives.
2. Ignored Customer Alerts: The firm reportedly received numerous notifications regarding injuries and deaths linked to these malfunctions, yet adequate remedial measures were not executed to tackle these serious concerns.
3. Inadequate Response: Baxter's responses to these defects, involving customer alerts, were alleged to have been insufficient, demonstrating a lack of urgency in addressing design flaws that led to ongoing risks.
4. False Representation: Statements made by Baxter about the safety, effectiveness, rollout, and sales forecasts of the Novum LVPs were claimed to be materially misleading, failing to reflect the reality of the product's risks.

What Should Affected Investors Do?
Investors who believe they suffered losses in Baxter International during the aforementioned timeframe are encouraged to take swift action. By reaching out to Levi & Korsinsky by December 15, 2025, they can request to be appointed as lead plaintiffs in the case. Importantly, participation in this lawsuit does not necessitate serving as a lead plaintiff to benefit from any recovery that might arise from court proceedings.

If you're an affected investor, you can reach out to the firm directly for assistance. An email to Joseph E. Levi, Esq. is a possible first step—details below:

• - Email: [redacted]
• - Phone: (212) 363-7500

No Financial Risk for Investors
One significant aspect investors should note is that participation in this class action may not require any out-of-pocket expenses. If you qualify as a class member, you might be eligible for compensation without incurring any fees, making this a viable option for those seeking recourse without financial strain.

Why Choose Levi & Korsinsky?
Levi & Korsinsky boasts a formidable track record, having secured hundreds of millions in settlements for wronged shareholders. With extensive experience in managing securities litigation, their dedicated team is well-equipped to handle high-stakes cases. For seven consecutive years, they ranked prominently in the top tier of securities litigation firms nationwide as detailed by ISS Securities Class Action Services.

Conclusion
Baxter International, Inc. investors should remain vigilant and proactive. Engaging with legal experts at Levi & Korsinsky could provide much-needed support and clarity in this complex situation. If you've experienced losses during the specified period, don’t hesitate—connect with Levi & Korsinsky before time runs out.

Contact Information
For more details or to consult with a legal representative, please reach out to:

• - Joseph E. Levi, Esq.
• - At: 33 Whitehall Street, 27th Floor, New York, NY 10004
• - Email: [redacted]
• - Tel: (212) 363-7500

Do not miss the chance to protect your rights and potential recoveries related to Baxter International, Inc. and take necessary actions before the critical deadline.